Home > News Center > Medical Sciences > Professor Zeng Yixin Appointed as Chief Expert of Clinical Pathway Technology Review Committee

Professor Zeng Yixin Appointed as Chief Expert of Clinical Pathway Technology Review Committee

Last updated :2009-09-14

Translated by Eric Shi

According to the news source from Ministry of Health, Professor Zeng Yixin, Fellow of Chinese Academy of Sciences and Head of the Affiliated Cancer Hospital of SYSU was recently appointed as the chief expert of the Clinical Pathway Technology Review Committee, and Profess Jiang Wenqi recruited as member of Oncology Group of the Committee.

As a standardized management approach, clinical pathway was originated in the United States and other Western countries, and has more than 20 years of history. The modern management philosophy of Clinical pathway includes quality management, evidence-based medicine and the patient-centered management,ensuring the refinement,standardization, programmed, and nonrandomizezation of the treatment to improve the efficiency of the management and utilization of hospital resources, to enhance the control of the clinical risk, to shorten the hospitalization period and to reduce the treatment costs. Therefore, the applications and exploration of the medical quality management of the clinical path studies is significant in terms of improving the medical treatment quality, control of the medical fees, shortening the hospitalization period and promoting the efficiency of medical recourses utilization. To that end, Ministry of Health decided to establish Clinical Pathway Technology Review Committee, inviting 10 Fellows of Chinese Academy of Sciences and Chinese Academy of Engineering as chief expert members, and 204 well-known experts from 22 clinical related disciplines as members of the expert group. Professor Zeng Yixin, from the Affiliated Cancer Hospital of SYSU and Fellow of Chinese Academy of Sciences, and Professor Jiang Wenqi were both appointed as members of the Committee.

The source said that, members of the Committee will serve for a three-year term, responsible for the review of the research and application of clinical pathway and providing technical consultancy for the pilot programme of the clinical pathway.